NCT06672276 - To Evaluate the Pharmacokinetics and Safety of TQD3606 for Injection in Subjects With Renal Insufficiency | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

November 30, 2024

Primary Completion Date

May 31, 2025

Study Completion Date

November 30, 2025

Conditions

Resistant to Gram-positive, Gram-negative and Anaerobic Bacteria

Interventions

DRUG

TQD3606

TQD3606 is a fixed-dose combination of meropenem and avibactam. Meropenem is a carbapenem antimicrobial agent, and avibactam is a β-lactamase inhibitor.

Trial Locations (2)

250014

The First Affiliated Hospital of Shandong First Medical University (Shandong Qianfoshan Hospital), Jinan

The Second Hospital of Shandong University, Jinan